	US 12,221,471 B2
	Nanocarriers for lung inflammation therapy
Natalia Higuita-Castro, Columbus, OH (US); Daniel Gallego-Perez, Columbus, OH (US); Samir Ghadiali, Upper Arlington, OH (US); Joshua Englert, Powell, OH (US); and Chandan Sen, Columbus, OH (US)
Assigned to Ohio State Innovation Foundation, Columbus, OH (US)
Appl. No. 17/284,286
Filed by Ohio State Innovation Foundation, Columbus, OH (US)
PCT Filed Oct. 18, 2019, PCT No. PCT/US2019/056997 § 371(c)(1), (2) Date Apr. 9, 2021, PCT Pub. No. WO2020/081974, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/747,987, filed on Oct. 19, 2018.
Prior Publication US 2021/0332106 A1, Oct. 28, 2021
Int. Cl. C07K 14/785 (2006.01); A61K 9/51 (2006.01); A61K 38/17 (2006.01); A61P 11/00 (2006.01); C12N 15/88 (2006.01)

CPC C07K 14/785 (2013.01) [A61K 9/51 (2013.01); A61K 38/17 (2013.01); A61P 11/00 (2018.01); C12N 15/88 (2013.01)]

4 Claims

1. An extracellular vesicle for treating Acute Respiratory Distress Syndrome (ARDS) produced by a method comprising:

i) nanotransfecting skin cells with a non-viral vector encoding a fusion protein comprising:

a) surfactant protein-A (SPA) capable of binding P63/CKAP4 or CD200 capable of binding CD200R and

b) a heterologous exosomal or lysosomal transmembrane protein under conditions suitable for extracellular vesicle secretion, and

ii) collecting the extracellular vesicles produced by the skin cells comprising the fusion protein, and wherein the extracellular vesicles are loaded with a therapeutic cargo, the heterologous exosomal protein or lysosomal transmembrane protein is inserted into the EV membrane and the SPA or CD200 protein are capable of binding P63/CKAP4 or CD200R.